Altimmune (ALT) is discontinuing further development of AdCOVID

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. AA
10. TECHM:IN

Go back to Altimmune (ALT) is discontinuing further development of AdCOVID

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial

June 29, 2021 4:01 PM EDT

AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteersAltimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programsAltimmune also provides an update on its T-COVID Phase 1/2 Clinical Trial

GAITHERSBURG, Md., June 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided... More